TCON

TRACON Pharmaceuticals, Inc. (TCON) | Rumor.io

TRACON Pharmaceuticals

TCON

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TCON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 1

TRACON Pharmaceuticals, Inc. ($TCON) has terminated its ENVASARC trial due to the primary endpoint not being met, with an objective response rate of 5% in 82 evaluable patients.
The company will focus on exploring strategic alternatives, including a potential merger, acquisition, or sale of assets, and will leverage its in-house Product Development Platform to reduce costs and increase efficiency.
The average price target for TRACON Pharmaceuticals is $30.50, with forecasts ranging from $6.00 to $55.00, representing a potential increase of 2% from the last closing price of $1.43.

Generated by AI

Sentiment

Of the messages about TCON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.3% +54.12
Bearish	—	—	—	2.7% -54.12

Bullish· Mar 22

$TCON could trend back towards 1.5-2 area next week if it reports positive results with ORR in double digits.
The stock has the potential to explode up 700% in one day, with accumulation and very little resistance now between its current price and a dollar.
With positive phase 3 trial results for its drug candidate Imarasib in treating pancreatic cancer and an analyst upgrade citing commercial potential, $TCON stock gained 17.4731% pre-market.

Bearish· Nov 14

TRACON Pharmaceuticals, Inc. (TCON) has seen significant volume, with trading 168% and 100% above average volume, respectively, and the stock down -16.36% and -13.55%.
The company is expected to announce a reverse split this week, which could lead to a significant decline in the stock's value.
TRACON Pharmaceuticals, Inc. has struggled to maintain its price, with the stock unable to hold above 25 cents and potentially heading to an all-time low of 17 cents.

Generated by AI

Topics

Of the messages about TCON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	9.09%
Controversies	—	—	—	30.3%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	60.61%

Earnings· Nov 5

TRACON Pharmaceuticals, Inc. ($TCON) reported Q1 GAAP EPS of -$0.17, beating estimates by $0.03.
The company's cash and cash equivalents stood at $19.1M as of the earnings announcement.
TRACON Pharmaceuticals is scheduled to post quarterly earnings on November 5th, 2019.

Analysts· Feb 24

TRACON Pharmaceuticals, Inc. ($TCON) has received coverage from multiple analysts, including Wells Fargo, Oppenheimer, Stifel Nicolaus, and Needham & Company LLC.
Analysts have initiated coverage with buy ratings and price targets ranging from $16 to $22, with a consensus price target of $19.00.
4-star analyst Yigal Nochomovitz from Oppenheimer has a 67% success rate and has rated $TCON as a buy, citing its potential for significant upside.

Announcements· Apr 10

TRACON Pharmaceuticals, Inc. (TCON) is down -13.74% in the pre-market.
The decline is not accompanied by any specific reasons or explanations.
The post does not mention any company announcements or updates.

Technical Analysis· Jan 24

Technical analysis suggests a potential breakout above $4.51, with a possible leg up to $5.02.
The stock has been showing strong accumulation, building a new base before the next leg up, with volume indicating a strong indicator of a potential rise.
The stock is currently averaging up, with a potential target of $5, and a possible push past $4.24 in the near future.

Generated by AI

Community

Of the messages about TCON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	74.14%
Newcomers	—	—	—	25.86%

Regulars· Nov 21

TRACON Pharmaceuticals, Inc. ($TCON) is up 24.50% in the pre-market, a significant increase from its average volume.
$TCON stock has traded 2425% above average volume, resulting in a 12.39% increase, with some participants questioning whether this rise will continue.
The high trading volume of $TCON, exceeding the float of 23.7M shares, is noteworthy, with some participants highlighting the unusual volume as a notable aspect of the stock's performance.

Newcomers· Dec 20

TRACON Pharmaceuticals' ENVASARC trial has shown positive results, with the company providing an update on the ongoing pivotal phase 2 trial.
The stock has experienced significant price increases, with a 60% gain in pre-market trading and a 56% gain at close, making it a notable performer in the penny stock market.
New investors are taking notice of the stock's performance, with some traders managing their positions and others waiting to see if the stock will continue to rise or pull back to a lower risk entry point.

Generated by AI

Also Discussed

Investors talking about TCON also mention

#	Name	Attention
1	SYBX - Synlogic, Inc.	——
2	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
3	MYOV - Myovant Sciences Ltd.	——
4	ASLN - ASLAN Pharmaceuticals Limited	——
5	RGLS - Regulus Therapeutics Inc.	——
6	VBIV - VBI Vaccines Inc.	——
7	Verastem Inc.VSTM	0%0
8	KRTX - Karuna Therapeutics, Inc.	——
9	ONCT - Oncternal Therapeutics, Inc.	——
10	I-Mab Sponsored ADRIMAB	0%0